Pfizer Ventures

Pfizer Ventures is the corporate venture capital arm of Pfizer Inc., dedicated to investing in innovative healthcare companies across various stages of development. With a capital commitment of $900 million, the firm primarily focuses on early-stage opportunities but also considers investments in start-ups and spinouts. While its investments are primarily U.S.-focused, international investments may represent up to 20% of the portfolio. Pfizer Ventures can lead or join a syndicate of investors and seeks board representation commensurate with its investment. The firm's investment strategy centers on therapeutics, emphasizing areas such as Inflammation & Immunology, Internal Medicine, Oncology, Anti-Infectives, and Vaccines. Additionally, Pfizer Ventures considers platform technologies, diagnostics, drug delivery, pharmaceutical services, and other technologies that have the potential to transform drug discovery and development. The firm is an active investor, working closely with management to develop product strategy and shareholder value, bringing a pharmaceutical perspective and access to Pfizer's internal networks and expertise. Pfizer Ventures has a streamlined approval process for investment decisions, and all investments have the potential for a business relationship with Pfizer. The firm emphasizes its ability to lead or join a syndicate of investors and seeks board representation commensurate with its investment. This approach allows Pfizer Ventures to actively support its portfolio companies throughout their growth cycles, contributing strategic guidance in addition to capital and access to Pfizer's expertise when appropriate.

Innovative healthcare solutions, Alignment with Pfizer's therapeutic areas, Potential for strategic partnership with Pfizer, Strong management team, Scalable business model, Clear regulatory pathway, Competitive market positioning, Demonstrated clinical or preclinical efficacy, Potential for significant patient impact, Ability to leverage Pfizer's global reach